Kalra Sanjay
Department of Endocrinology, Bharati Hospital, Karnal, Haryana, India.
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):564-7. doi: 10.4103/2230-8210.180644.
This study aimed to document the utility and safety of insulin degludec (IDeg) and insulin degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast. An observational study was conducted at a single center, in the real world setting, on six persons who either switched to IDeg or IDegAsp a month before Ramadan or changed time of administration of IDegAsp at the onset of Ramadan, to keep the fast in a safe manner. Subjects were kept under regular monitoring and surveillance before, during, and after Ramadan, and counseled in an opposite manner. Four persons, who shifted from premixed insulin to IDegAsp, experienced a 12-18% dose reduction after 14 days. At the onset of Ramadan, the Suhur dose was reduced by 30%, and this remained unchanged during the fasting month. The Iftar dose had to be increased by 4 units. One person who shifted from neutral protamine hagedorn to IDeg demonstrated a 25% dose reduction at 20 days, without any further change in insulin requirement during Ramadan. One person who changed time of injection of IDegAsp from morning to night reported no change in dosage. No episode of major hypoglycemia was reported. IDeg and IDegAsp are effective, safe, and well-tolerated means of achieving glycemic control in persons with type 2 diabetes who wish to fast.
本研究旨在记录德谷胰岛素（IDeg）和德谷门冬胰岛素（IDegAsp）在2型糖尿病患者中进行斋月禁食期间的效用和安全性。在一个单一中心的真实环境中，对6名在斋月前一个月改用IDeg或IDegAsp，或在斋月开始时改变IDegAsp给药时间以安全禁食的患者进行了一项观察性研究。在斋月前、期间和之后对受试者进行定期监测和监督，并给予相反的建议。4名从预混胰岛素改用IDegAsp的患者在14天后剂量降低了12%-18%。在斋月开始时，晨礼剂量降低了30%，在禁食月期间保持不变。开斋剂量必须增加4单位。1名从中性鱼精蛋白锌胰岛素改用IDeg的患者在20天时剂量降低了25%，在斋月期间胰岛素需求量没有进一步变化。1名将IDegAsp注射时间从早晨改为晚上的患者报告剂量没有变化。未报告严重低血糖事件。对于希望禁食的2型糖尿病患者，IDeg和IDegAsp是实现血糖控制的有效、安全且耐受性良好的方法。
